Synthesis Med Chem (UK) Limited
Registered name: SYNTHESIS MED CHEM (UK) LIMITED
Synthesis Med Chem (UK) Limited made £629k revenue and a £117k loss in the year to 31 Dec 2025.
Synthesis Med Chem (UK) Limited’s revenue fell 52% to £629k in the year to 31 Dec 2025, with a loss of £117k and 5 employees. The company is classified under “research and experimental development on biotechnology” and is based in London; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- London, London
- Age
- 15 yrs · since 2011
- Type
- Private Limited Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 30 Jun 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L | Full P&L |
| Profit & loss | ||||
| Revenue (turnover) | £409k | £1.1m | £1.3m | £629k |
| Cost of sales | £238k | £639k | £811k | £406k |
| Gross profit | £171k | £490k | £488k | £223k |
| Operating profit | — | £49.4k | £18.1k | −£133k |
| Profit before tax | −£165k | £49.4k | £21.8k | −£129k |
| Profit after tax | −£161k | £39.8k | £17.5k | −£117k |
| Profit (best available) | −£161k | £39.8k | £17.5k | −£117k |
| Staff costs | £146k | £418k | £338k | £457k |
| Employees (average) | 1 | 4 | 5 | 5 |
| Ratios | ||||
| Profit margin | −39.4% | 3.5% | 1.4% | −18.6% |
| Gross margin | 41.9% | 43.4% | 37.6% | 35.4% |
| Revenue per employee | £409k | £282k | £260k | £126k |
| Profit per employee | −£161k | £9.9k | £3.5k | −£23.5k |
| Growth (year on year) | ||||
| Revenue growth | — | — | — | ▼51.6% |
| Profit growth | — | — | — | ▼770.9% |
| Headcount growth | — | — | — | 0% |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £802k | £1.3m | £1.5m | £230k |
| Net assets | £34.2k | £74k | £91.5k | −£25.8k |
| Fixed assets | £0 | £0 | £0 | £1.7k |
| Current assets | £2.1m | £2.7m | £2.9m | £3m |
| Debtors | £27.5k | £179k | £173k | £74.2k |
| Deferred income | £2.9k | £3.8k | £13.2k | £13.7k |
| Source | FullAccounts · bulk data Sep 2024 | FullAccounts · bulk data Sep 2024 | FullAccounts · bulk data Jul 2025 | FullAccounts · bulk data Sep 2026 |
How the business works
- Profit margin
- −18.6%
- Profit ÷ revenue.
- Gross margin
- 35.4%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £126k
- Revenue ÷ average employees.
- Profit per employee
- −£23.5k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 0.3%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 2.2%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 11.8%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼128%
- Now −£25.8k
- Cash at bank
- ▼84%
- Now £230k
- Headcount
- 0%
- Now 5
- Deferred income
- ▲4%
- Now £13.7k
- Fixed assets
- —
- Now £1.7k
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Similar profitable businesses
- Collaborative Community Against Coronavirus CICLondon · Research and experimental development on biotechnology
- Revenue
- £786k
- Profit
- £29.9k
- Staff
- 0
- Nuritas UK LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £88.8k
- Staff
- 4
- Adorx Therapeutics LimitedEdinburgh · Research and experimental development on biotechnology
- Revenue
- £1.2m
- Profit
- £211k
- Staff
- 0
- Clinicology Ltd.Guildford · Research and experimental development on biotechnology
- Revenue
- £1.4m
- Profit
- £79.1k
- Staff
- 7
Sources
Latest figures from FullAccounts for the year to 31 Dec 2025 (profit −£117k), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.